Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Research Report 2023

Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Research Report 2023

Table of Contents
1 Antidiabetic Glucagon-like Peptide 1 Agonists Market Overview
1.1 Product Overview and Scope of Antidiabetic Glucagon-like Peptide 1 Agonists
1.2 Antidiabetic Glucagon-like Peptide 1 Agonists Segment by Type
1.2.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Value Comparison by Type (2023-2029)
1.2.2 Exenatied
1.2.3 Liraglutide
1.2.4 Lixisenatide
1.2.5 Albiglutide
1.2.6 Dulaglutide
1.3 Antidiabetic Glucagon-like Peptide 1 Agonists Segment by Application
1.3.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size Estimates and Forecasts
1.4.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue 2018-2029
1.4.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales 2018-2029
1.4.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Antidiabetic Glucagon-like Peptide 1 Agonists Market Competition by Manufacturers
2.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Manufacturers (2018-2023)
2.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Manufacturers (2018-2023)
2.4 Global Antidiabetic Glucagon-like Peptide 1 Agonists Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists, Product Type & Application
2.7 Antidiabetic Glucagon-like Peptide 1 Agonists Market Competitive Situation and Trends
2.7.1 Antidiabetic Glucagon-like Peptide 1 Agonists Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antidiabetic Glucagon-like Peptide 1 Agonists Players Market Share by Revenue
2.7.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antidiabetic Glucagon-like Peptide 1 Agonists Retrospective Market Scenario by Region
3.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region: 2018-2029
3.2.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region: 2018-2023
3.2.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region: 2024-2029
3.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region: 2018-2029
3.3.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region: 2018-2023
3.3.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region: 2024-2029
3.4 North America Antidiabetic Glucagon-like Peptide 1 Agonists Market Facts & Figures by Country
3.4.1 North America Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2029)
3.4.3 North America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Market Facts & Figures by Country
3.5.1 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2029)
3.5.3 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Market Facts & Figures by Country
3.6.1 Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2029)
3.6.3 Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Market Facts & Figures by Country
3.7.1 Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2029)
3.7.3 Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Market Facts & Figures by Country
3.8.1 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2029)
3.8.3 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2018-2029)
4.1.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2018-2023)
4.1.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2024-2029)
4.1.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Type (2018-2029)
4.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Type (2018-2029)
4.2.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Type (2018-2023)
4.2.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Type (2024-2029)
4.2.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Type (2018-2029)
4.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Price by Type (2018-2029)
5 Segment by Application
5.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2029)
5.1.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2023)
5.1.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2024-2029)
5.1.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Application (2018-2029)
5.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Application (2018-2029)
5.2.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Application (2018-2023)
5.2.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Application (2024-2029)
5.2.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Application (2018-2029)
5.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue and Gross Margin (2018-2023)
6.2.4 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Eli Lily
6.3.1 Eli Lily Corporation Information
6.3.2 Eli Lily Description and Business Overview
6.3.3 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Product Portfolio
6.3.5 Eli Lily Recent Developments/Updates
6.4 GSK
6.4.1 GSK Corporation Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue and Gross Margin (2018-2023)
6.4.4 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antidiabetic Glucagon-like Peptide 1 Agonists Industry Chain Analysis
7.2 Antidiabetic Glucagon-like Peptide 1 Agonists Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antidiabetic Glucagon-like Peptide 1 Agonists Production Mode & Process
7.4 Antidiabetic Glucagon-like Peptide 1 Agonists Sales and Marketing
7.4.1 Antidiabetic Glucagon-like Peptide 1 Agonists Sales Channels
7.4.2 Antidiabetic Glucagon-like Peptide 1 Agonists Distributors
7.5 Antidiabetic Glucagon-like Peptide 1 Agonists Customers
8 Antidiabetic Glucagon-like Peptide 1 Agonists Market Dynamics
8.1 Antidiabetic Glucagon-like Peptide 1 Agonists Industry Trends
8.2 Antidiabetic Glucagon-like Peptide 1 Agonists Market Drivers
8.3 Antidiabetic Glucagon-like Peptide 1 Agonists Market Challenges
8.4 Antidiabetic Glucagon-like Peptide 1 Agonists Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Competitive Situation by Manufacturers in 2022
Table 4. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (Units) of Key Manufacturers (2018-2023)
Table 5. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Antidiabetic Glucagon-like Peptide 1 Agonists Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Antidiabetic Glucagon-like Peptide 1 Agonists, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists, Product Type & Application
Table 12. Global Key Manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antidiabetic Glucagon-like Peptide 1 Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antidiabetic Glucagon-like Peptide 1 Agonists as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2018-2023) & (Units)
Table 18. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Region (2018-2023)
Table 19. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2024-2029) & (Units)
Table 20. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Region (2024-2029)
Table 21. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Region (2018-2023)
Table 23. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Region (2024-2029)
Table 25. North America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2023) & (Units)
Table 27. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2024-2029) & (Units)
Table 28. North America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2023) & (Units)
Table 32. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2024-2029) & (Units)
Table 33. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2018-2023) & (Units)
Table 37. Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2024-2029) & (Units)
Table 38. Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2023) & (Units)
Table 42. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2024-2029) & (Units)
Table 43. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2023) & (Units)
Table 47. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2024-2029) & (Units)
Table 48. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (Units) by Type (2018-2023)
Table 51. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (Units) by Type (2024-2029)
Table 52. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Type (2018-2023)
Table 53. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Type (2024-2029)
Table 54. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Type (2018-2023)
Table 57. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Type (2024-2029)
Table 58. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price (US$/Unit) by Type (2018-2023)
Table 59. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price (US$/Unit) by Type (2024-2029)
Table 60. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (Units) by Application (2018-2023)
Table 61. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (Units) by Application (2024-2029)
Table 62. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Application (2018-2023)
Table 63. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Application (2024-2029)
Table 64. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Application (2018-2023)
Table 67. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Application (2024-2029)
Table 68. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price (US$/Unit) by Application (2018-2023)
Table 69. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price (US$/Unit) by Application (2024-2029)
Table 70. Novo Nordisk Corporation Information
Table 71. Novo Nordisk Description and Business Overview
Table 72. Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 74. Novo Nordisk Recent Developments/Updates
Table 75. AstraZeneca Corporation Information
Table 76. AstraZeneca Description and Business Overview
Table 77. AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 79. AstraZeneca Recent Developments/Updates
Table 80. Eli Lily Corporation Information
Table 81. Eli Lily Description and Business Overview
Table 82. Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 84. Eli Lily Recent Developments/Updates
Table 85. GSK Corporation Information
Table 86. GSK Description and Business Overview
Table 87. GSK Antidiabetic Glucagon-like Peptide 1 Agonists Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. GSK Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 89. GSK Recent Developments/Updates
Table 90. Sanofi Corporation Information
Table 91. Sanofi Description and Business Overview
Table 92. Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 94. Sanofi Recent Developments/Updates
Table 95. Bristol-Myers Squibb Corporation Information
Table 96. Bristol-Myers Squibb Description and Business Overview
Table 97. Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 99. Bristol-Myers Squibb Recent Developments/Updates
Table 100. Key Raw Materials Lists
Table 101. Raw Materials Key Suppliers Lists
Table 102. Antidiabetic Glucagon-like Peptide 1 Agonists Distributors List
Table 103. Antidiabetic Glucagon-like Peptide 1 Agonists Customers List
Table 104. Antidiabetic Glucagon-like Peptide 1 Agonists Market Trends
Table 105. Antidiabetic Glucagon-like Peptide 1 Agonists Market Drivers
Table 106. Antidiabetic Glucagon-like Peptide 1 Agonists Market Challenges
Table 107. Antidiabetic Glucagon-like Peptide 1 Agonists Market Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Antidiabetic Glucagon-like Peptide 1 Agonists
Figure 2. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Share by Type in 2022 & 2029
Figure 4. Exenatied Product Picture
Figure 5. Liraglutide Product Picture
Figure 6. Lixisenatide Product Picture
Figure 7. Albiglutide Product Picture
Figure 8. Dulaglutide Product Picture
Figure 9. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 10. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Share by Application in 2022 & 2029
Figure 11. Hospital
Figure 12. Pharmacy
Figure 13. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size (2018-2029) & (US$ Million)
Figure 15. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (2018-2029) & (Units)
Figure 16. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price (US$/Unit) & (2018-2029)
Figure 17. Antidiabetic Glucagon-like Peptide 1 Agonists Report Years Considered
Figure 18. Antidiabetic Glucagon-like Peptide 1 Agonists Sales Share by Manufacturers in 2022
Figure 19. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Share by Manufacturers in 2022
Figure 20. The Global 5 and 10 Largest Antidiabetic Glucagon-like Peptide 1 Agonists Players: Market Share by Revenue in 2022
Figure 21. Antidiabetic Glucagon-like Peptide 1 Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 22. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 23. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Country (2018-2029)
Figure 24. North America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Country (2018-2029)
Figure 25. United States Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Canada Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Country (2018-2029)
Figure 28. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Country (2018-2029)
Figure 29. Germany Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. France Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. U.K. Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Italy Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Russia Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Region (2018-2029)
Figure 35. Asia Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Region (2018-2029)
Figure 36. China Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Japan Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. South Korea Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. India Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Australia Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. China Taiwan Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Indonesia Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Thailand Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Malaysia Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Country (2018-2029)
Figure 46. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Country (2018-2029)
Figure 47. Mexico Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Brazil Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Argentina Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Country (2018-2029)
Figure 51. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Country (2018-2029)
Figure 52. Turkey Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. UAE Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Global Sales Market Share of Antidiabetic Glucagon-like Peptide 1 Agonists by Type (2018-2029)
Figure 56. Global Revenue Market Share of Antidiabetic Glucagon-like Peptide 1 Agonists by Type (2018-2029)
Figure 57. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price (US$/Unit) by Type (2018-2029)
Figure 58. Global Sales Market Share of Antidiabetic Glucagon-like Peptide 1 Agonists by Application (2018-2029)
Figure 59. Global Revenue Market Share of Antidiabetic Glucagon-like Peptide 1 Agonists by Application (2018-2029)
Figure 60. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price (US$/Unit) by Application (2018-2029)
Figure 61. Antidiabetic Glucagon-like Peptide 1 Agonists Value Chain
Figure 62. Antidiabetic Glucagon-like Peptide 1 Agonists Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Cetrimide Market Insights, Forecast to 2029

Published: 22-Sep-2023        Price: US 4900 Onwards        Pages: 91

Cetrimide is an antiseptic agent, meaning it has various antibacterial, antifungal and other antimicrobial properties and can be applied to skin or mucous membranes to avoid or minimize the risk of infection. It is also a surfactant, meaning it functions as a detergent with cleaning properties. The global Cetrimide market is projected to grow from US$ 317.1 million in 2023 to US$ 437.2 million by 2029, at a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period. Indi......

Global Antivenom Market Insights, Forecast to 2029

Published: 22-Sep-2023        Price: US 4900 Onwards        Pages: 107

Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. They are only recommended if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection. The global Antivenom market is projected to grow from US$ 1002.9 million in 2023 to US$ 1283.7 million by 2029, at a Compound Annual Growth ......

Global Swine Vaccines Market Insights, Forecast to 2029

Published: 22-Sep-2023        Price: US 4900 Onwards        Pages: 117

The immune system responds by producing antibodies that destroy the infectious agents, usually in co-operation with specialised body cells or by neutralising the toxins that are responsible for the disease. This process of stimulating immunity is called vaccination. Vaccines contain antigens from viruses, bacteria, bacterial toxins, or parasites. They are given to pigs, usually by injection, to stimulate an immune response which will protect the pigs against later natural infection ......

Global Rho Associated Protein Kinase 2 Market Insights, Forecast to 2029

Published: 22-Sep-2023        Price: US 4900 Onwards        Pages: 77

Rho associated coiled-coil containing protein kinase 2 is a protein that in humans is encoded by the ROCK2 gene. The protein encoded by this gene is a serine/threonine kinase that regulates cytokinesis, smooth muscle contraction, the formation of actin stress fibers and focal adhesions, and the activation of the c-fos serum response element. This protein, which is an isozyme of ROCK1, is a target for the small GTPase Rho. Market Analysis and Insights: Global Rho Associated Protein Kinase ......

Global Hyperimmune Globulins Market Insights, Forecast to 2029

Published: 22-Sep-2023        Price: US 4900 Onwards        Pages: 110

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccine......

Global Non-Radioactive Nucleic Acid Labeling Product Market Insights, Forecast to 2029

Published: 22-Sep-2023        Price: US 4900 Onwards        Pages: 110

In recent years, non-radioactive nucleic acid labeling and detection methodologies have become available in response to a desire by researchers and their institutions to move away from the use of radioisotopes. Advancements made in the areas of chemiluminescence and fluorescence have allowed for an easier transition. In non-radioactive assays, signal is generated through an enzymatic reaction with a chemiluminescent or chromogenic substrate; alternatively, detection can occur through the appropr......

Global Oral Mucositis Drugs Market Insights, Forecast to 2029

Published: 22-Sep-2023        Price: US 4900 Onwards        Pages: 113

Oral mucositis is the most common complication of chemotherapy, and occurs usually in the people suffering from head and neck cancer. It causes damage to mucosal lining of the mouth which results in formation of ulcers and infections. The disease occurs usually occurs after 5 to 10 days of a chemotherapy process in cancer patients. Oral mucositis leads to different problems such as severe pain in mouth, lack of nutrition due to inability to eat, increased risk of infections due to open sores in ......

Global Sugar Coated Tablets Market Insights, Forecast to 2029

Published: 22-Sep-2023        Price: US 4900 Onwards        Pages: 108

Sugar Coated Tablets are coated with a colored or an uncolored sugar layer. The coating is water soluble and quickly dissolves after swallowing. The sugar-coating protects the encapsulated drug from the environment and provides a barrier to objectionable tablet taste or odor. Market Analysis and Insights: Global Sugar Coated Tablets Market The global Sugar Coated Tablets market is projected to grow from US$ 1640.3 million in 2023 to US$ 1793.5 million by 2029, at a Compound Annual ......

Global Recombinant Trypsin Solution Market Insights, Forecast to 2029

Published: 22-Sep-2023        Price: US 4900 Onwards        Pages: 106

Recombinant Trypsin is a genetically engineered protein expressed in E-Coli. As such it is totally animal free, free from contaminating enzymes like chymotrysin as well as protease inhibitors. It is highly stable with a high purity. It is widely used in insulin manufacturing, Vaccines Manufacturing and cell culture applications. The global Recombinant Trypsin Solution market is projected to grow from US$ 25 million in 2023 to US$ 39 million by 2029, at a Compound Annual Growth Rate (CAGR)......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs